Inflammatory Bowel Disease

Genomic and Personalized Medicine, Two-Vol Set

Volumn , Issue , 2009, Pages 1040-1055

  Van Bodegraven, A ^a   Wijmenga, Cisca ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 80052198090     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-369420-1.00086-X     Document Type: Chapter

References (153)

1. Abreu M.T., Taylor K.D., Lin Y.C., Hang T., Gaiennie J., Landers C.J., Vasiliauskas E.A., Kam L.Y., Rojany M., Papadakis K.A., et al. Mutations in NOD2 are associated with fibrostenosing disease in patients with Crohn's disease. Gastroenterology 2002, 123(3):679-688.
2. Achkar J.P., Dassopoulos T., Silverberg M.S., Tuvlin J.A., Duerr R.H., Brant S.R., Siminovitch K., Reddy D., Datta L.W., Bayless T.M., et al. Phenotype-stratified genetic linkage study demonstrates that IBD2 is an extensive ulcerative colitis locus. Am J Gastroenterol 2006, 101(3):572-580.
3. Altshuler D., Brooks L.D., Chakravarti A., Collins F.S., Daly M.J., Donnelly P. International HapMap Consortium. A haplotype map of the human genome. Nature 2005 Oct 27, 437(7063):1299-1320.
4. Alvarez-Lobos M., Arostegui J.I., Sans M., Tassies D., Plaza S., Delgado S., Lacy A.M., Pique J.M., Yague J., Panes J. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 2005, 242(5):693-700.
5. Andres P.G., Friedman L.S. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am 1999, 28(2):255-281. vii.
6. Arnott I.D., Nimmo E.R., Drummond H.E., Fennell J., Smith B.R., MacKinlay E., Morecroft J., Anderson N., Kelleher D., O'Sullivan M., et al. NOD2/CARD15, TLR4 and CD14 mutations in Scottish and Irish Crohn's disease patients: Evidence for genetic heterogeneity within Europe?. Genes Immun 2004, 5(5):417-425.
7. Bach J.F. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002 Sep 19, 347(12):911-920.
8. Bagnoli S., Putignano A.L., Melean G., Baglioni S., Sestini R., Milla M., d'Albasio G., Genuardi M., Pacini F., Trallori G., et al. Susceptibility to refractory ulcerative colitis is associated with polymorphism in the hMLH1 mismatch repair gene. Inflamm Bowel Dis 2004, 10(6):705-708.
9. Bibiloni R., Fedorak R.N., Tannock G.W., Madsen K.L., Gionchetti P., Campieri M., De Simone C., Sartor R.B. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 2005, 100(7):1539-1546.
10. Bild A.H., Yao G., Chang J.T., Wang Q., Potti A., Chasse D., Joshi M.B., Harpole D., Lancaster J.M., Berchuck A., et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006 Jan 19, 439(7074):353-357.
11. Bonen D.K., Cho J.H. The genetics of inflammatory bowel disease. Gastroenterology 2003, 124(2):521-536.
12. Bouma G., Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003, 3(7):521-533.
13. Bouma G., Crusius J.B., Garcia-Gonzalez M.A., Meijer B.U., Hellemans H.P., Hakvoort R.J., Schreuder G.M., Kostense P.J., Meuwissen S.G., Pena A.S. Genetic markers in clinically well defined patients with ulcerative colitis (UC). Clin Exp Immunol 1999, 115(2):294-300.
14. Braat H., Rottiers P., Huyghebaert N., Zelinkova Z., Remaut E., Remon J.P., van Deventer S.J.H., Neirynck S., Peppelenbosch M.P., Steidler L.S., et al. Interleukin-10 producing Lactococcus lactis for the treatment of Crohn's disease. Gastroenterology 2005, 128(4Suppl 2):A104.
15. Buning C., Geerdts L., Fiedler T., Gentz E., Pitre G., Reuter W., Luck W., Buhner S., Molnar T., Nagy F., et al. DLG5 variants in inflammatory bowel disease. Am J Gastroenterol 2006, 101(4):786-792.
16. Burczynski M.E., Peterson R.L., Twine N.C., Zuberek K.A., Brodeur B.J., Casciotti L., Maganti V., Reddy P.S., Strahs A., Immermann F., et al. Molecular classification of Crohn's disease and ulcerative colitis patients using transcriptional profiles in peripheral blood mononuclear cells. J Mol Diagn 2006, 8(1):51-61.
17. Chamaillard M., Iacob R., Desreumaux P., Colombel J.F. Advances and perspectives in the genetics of inflammatory bowel diseases. Clin Gastroenterol Hepatol 2006, 4(2):143-151.
18. Colombel J.F., Ferrari N., Debuysere H., Marteau P., Gendre J.P., Bonaz B., Soule J.C., Modigliani R., Touze Y., Catala P., et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000, 118(6):1025-1030.
19. Corrao G., Tragnone A., Caprilli R., Trallori G., Papi C., Andreoli A., Di Paolo M., Riegler G., Rigo G.P., Ferrau O., et al. Risk of inflammatory bowel disease attributable to smoking, oral contraception and breastfeeding in Italy: A nationwide case-control study. Cooperative Investigators of the Italian Group for the Study of the Colon and the Rectum (GISC). Int J Epidemiol 1998, 27(3):397-404.
20. Costello C.M., Mah N., Hasler R., Rosenstiel P., Waetzig G.H., Hahn A., Lu T., Gurbuz Y., Nikolaus S., Albrecht M., et al. Dissection of the inflammatory bowel disease transcriptome using genome-wide cDNA microarrays. PLoS Med 2005, 2(8):e199.
21. Cosnes J. Tobacco and IBD: Relevance in the understanding of disease mechanisms and clinical practice. Best Pract Res Clin Gastroenterol 2004, 18(3):481-496.
22. Daly M.J., Pearce A.V., Farwell L., Fisher S.A., Latiano A., Prescott N.J., Forbes A., Mansfield J., Sanderson J., Langelier D., et al. Association of DLG5 R30Q variant with inflammatory bowel disease. Eur J Hum Genet 2005, 13(7):835-839.
23. Danese S., Sans M., Fiocchi C. Inflammatory bowel disease: The role of environmental factors. Autoimmun Rev 2004, 3(5):394-400.
24. de la Concha E.G., Fernandez-Arquero M., Lopez-Nava G., Martin E., Allcock R.J., Conejero L., Paredes J.G., Diaz-Rubio M. Susceptibility to severe ulcerative colitis is associated with polymorphism in the central MHC gene IKBL. Gastroenterology 2000, 119(6):1491-1495.
25. D'Haens G., Baert F., van Assche G., Caenepeel P., Vergauwe P., Tuynman H., De Vos M., van Deventer S., Stitt L., Donner A., Vermeire S., Van de Mierop F.J., Coche J.C., van der Woude J., Ochsenkühn T., van Bodegraven A.A., Van Hootegem P.P., Lambrecht G.L., Mana F., Rutgeerts P., Feagan B.G., Hommes D. Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients withnewly diagnosed Crohn's disease: an open randomised trial. Lancet 2008, 371(9613):660-667.
26. Dubinsky M.C., Lamothe S., Yang H.Y., Targan S.R., Sinnett D., Theoret Y., Seidman E.G. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000, 118(4):705-713.
27. Duerr R.H., Taylor K.D., Brant S.R., Rioux J.D., Silverberg M.S., Daly M.J., Steinhart A.H., Abraham C., Regueiro M., Griffiths A., et al. genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006 Dec 1, 314(5804):1461-1463.
28. Egan L.J., Derijks L.J., Hommes D.W. Pharmacogenomics in inflammatory bowel disease. Clin Gastroenterol Hepatol 2006, 4(1):21-28.
29. Ekbom A., Helmick C., Zack M., Adami H.O. The epidemiology of inflammatory bowel disease: A large, population-based study in Sweden. Gastroenterology 1991, 100(2):350-358.
30. Farrell R.J., Murphy A., Long A., Donnelly S., Cherikuri A., O'Toole D., Mahmud N., Keeling P.W., Weir D.G., Kelleher D. High multidrug resistance (P-glycoprotein 170) expression in inflammatory bowel disease patients who fail medical therapy. Gastroenterology 2000, 118(2):279-288.
31. Fasano A., Shea-Donohue T. Mechanisms of disease: The role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nat Clin Pract Gastroenterol Hepatol 2005, 2(9):416-422.
32. Feral C.C., Rose D.M., Han J., Fox N., Silverman G.J., Kaushansky K., Ginsberg M.H. Blocking the alpha 4 integrin-paxillin interaction selectively impairs mononuclear leukocyte recruitment to an inflammatory site. J Clin Invest 2006, 116(3):715-723.
33. Ferraris A., Torres B., Knafelz D., Barabino A., Lionetti P., de Angelis G.L., Iacono G., Papadatou B., D'Amato G., Di Ciommo V., et al. Relationship between CARD15, SLC22A4/5, and DLG5 polymorphisms and early-onset inflammatory bowel diseases: An Italian Multicentric Study. Inflamm Bowel Dis 2006, 12(5):355-361.
34. Fiocchi C. Inflammatory bowel disease: Etiology and pathogenesis. Gastroenterology 1998, 115(1):182-205.
35. Gallop J.H., Phillips S.F., Melton L.J., Zinsmeister A.R. Epidemiologic aspects of Crohn's disease: A population based study in Olmsted County, Minnesota. Gut 1998, 29:49-56.
36. Garcia Rodriguez L.A., Gonzalez-Perez A., Johansson S., Wallander M.A. Risk factors for inflammatory bowel disease in the general population. Aliment Pharmacol Ther 2005 Aug 15, 22(4):309-315.
37. Gasche C., Scholmerich J., Brynskov J., D'Haens G., Hanauer S.B., Irvine E.J., Jewell D.P., Rachmilewitz D., Sachar D.B., Sandborn W.J., et al. A simple classification of Crohn's disease: Report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000, 6(1):8-15.
38. Gazouli M., Mantzaris G., Archimandritis A.J., Nasioulas G., Anagnou N.P. Single nucleotide polymorphisms of OCTN1, OCTN2, and DLG5 genes in Greek patients with Crohn's disease. World J Gastroenterol 2005 Dec 21, 11(47):7525-7530.
39. Ghosh S., Goldin E., Gordon F.H., Malchow H.A., Rask-Madsen J., Rutgeerts P., Vyhnalek P., Zadorova Z., Palmer T., Donoghue S. Natalizumab Pan-European Study Group Natalizumab for active Crohn's disease. N Engl J Med 2003 Jan 2, 348(1):24-32.
40. Gionchetti P., Rizzello F., Helwig U., Venturi A., Lammers K.M., Brigidi P., Vitali B., Poggioli G., Miglioli M., Campieri M. Prophylaxis of pouchitis onset with probiotic therapy: A double-blind, placebo-controlled trial. Gastroenterology 2003, 124(5):1202-1209.
41. Guslandi M. Antibiotics for inflammatory bowel disease: Do they work?. Eur J Gastroenterol Hepatol 2005, 17(2):145-147.
42. Halfvarson J., Bodin L., Tysk C., Lindberg E., Jarnerot G. Inflammatory bowel disease in a Swedish twin cohort: A long-term follow-up of concordance and clinical characteristics. Gastroenterology 2003, 124(7):1767-1773.
43. Hampe J., Shaw S.H., Saiz R., Leysens N., Lantermann A., Mascheretti S., Lynch N.J., MacPherson A.J., Bridger S., van Deventer S., et al. Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet 1999, 65(6):1647-1655.
44. Hampe J., Cuthbert A., Croucher P.J., Mirza M.M., Mascheretti S., Fisher S., Frenzel H., King K., Hasselmeyer A., MacPherson A.J., et al. Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations. Lancet 2001 Jun 16, 357(9272):1925-1928.
45. Hampe J., Grebe J., Nikolaus S., Solberg C., Croucher P.J., Mascheretti S., Jahnsen J., Moum B., Klump B., Krawczak M., et al. Association of NOD2 (CARD 15) genotype with clinical course of Crohn's disease: A cohort study. Lancet 2002 May 11, 359(9318):1661-1665.
46. Hampe J., Franke A., Rosenstiel P., Till A., Teuber M., Huse K., Albrecht M., Mayr G., De La Vega F.M., Briggs J., et al. A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 2007, 39(2):207-211.
47. Hanauer S.B., Feagan B.G., Lichtenstein G.R., Mayer L.F., Schreiber S., Colombel J.F., Rachmilewitz D., Wolf D.C., Olson A., Bao W., et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial. Lancet 2002 May 4, 359(9317):1541-1549.
48. Hanauer S.B. Update on the etiology, pathogenesis and diagnosis of ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol 2004, 1(1):26-31.
49. Hart A.L., Lammers K., Brigidi P., Vitali B., Rizzello F., Gionchetti P., Campieri M., Kamm M.A., Knight S.C., Stagg A.J. Modulation of human dendritic cell phenotype and function by probiotic bacteria. Gut 2004, 53(11):1602-1609.
50. Hawkey C.J. Stem cell transplantation for Crohn's disease. Best Pract Res Clin Haematol 2004, 17(2):317-325.
51. Helio T., Halme L., Lappalainen M., Fodstad H., Paavola-Sakki P., Turunen U., Farkkila M., Krusius T., Kontula K. CARD15/NOD2 gene variants are associated with familially occurring and complicated forms of Crohn's disease. Gut 2003, 52(4):558-562.
52. Herrlinger K.R., Cummings J.R., Barnardo M.C., Schwab M., Ahmad T., Jewell D.P. The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet Genomics 2005, 15(10):705-711.
53. Hesterberg P.E., Winsor-Hines D., Briskin M.J., Soler-Ferran D., Merrill C., Mackay C.R., Newman W., Ringler D.J. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996, 111(5):1373-1380.
54. Hoffmeyer S., Burk O., von Richter O., Arnold H.P., Brockmoller J., Johne A., Cascorbi I., Gerloff T., Roots I., Eichelbaum M., et al. Functional polymorphisms of the human multidrug-resistance gene: Multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000 Mar 28, 97(7):3473-3478.
55. Hlavaty T., Pierik M., Henckaerts L., Ferrante M., Joossens S., van Schuerbeek N., Noman M., Rutgeerts P., Vermeire S. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease. Aliment Pharmacol Ther 2005 Oct 1, 22(7):613-626.
56. Hommes D., Baert F., van Assche G., Caenepeel F., Vergauwe P., Tuynman H., de Vos M., van Deventer S., Stitt L., Rutgeerts P., et al. The ideal management of Crohn's disease: Top down versusstep up strategies, a randomized controlled trial. Gastroenterology 2006, 130(4Suppl 2):A108.
57. Hughes L.B., Beasley T.M., Patel H., Tiwari H.K., Morgan S.L., Baggott J.E., Saag K.G., McNicholl J., Moreland L.W., Alarcon G.S., et al. Racial/ethnic differences in allele frequencies of single nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 2006, 26. [Epub ahead of print].
58. Hugot J.P., Chamaillard M., Zouali H., Lesage S., Cezard J.P., Belaiche J., Almer S., Tysk C., O'Morain C.A., Gassull M., et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 2001 May 31, 411(6837):599-603.
59. Hulsewe K.W., van der Hulst R.W., van Acker B.A., von Meyenfeldt M.F., Soeters P.B. Inflammation rather than nutritional depletion determines glutamine concentrations and intestinal permeability. Clin Nutr 2004, 23(5):1209-1216.
60. Israeli E., Goldin E., Shibolet O., Klein A., Hemed N., Engelhardt D., Rabbani E., Ilan Y. Oral immune regulation using colitis extracted proteins for treatment of Crohn's disease: Results of a phase I clinical trial. World J Gastroenterol 2005 May 28, 11(20):3105-3111.
61. Jenkins B., Holsten S., Bengmark S., Martindale R. Probiotics: A practical review of their role in specific clinical scenarios. Nutr Clin Pract 2005, 20(2):262-270.
62. Jiang L., Xia B., Li J., Ye M., Yan W., Deng C., Ding Y., Luo H., Hou W., Zhao Q., et al. Retrospective survey of 452 patients with inflammatory bowel disease in Wuhan city, central China. Inflamm Bowel Dis 2006, 12(3):212-217.
63. Karlinger K., Gyorke T., Mako E., Mester A., Tarjan Z. The epidemiology and the pathogenesis of inflammatory bowel disease. Eur J Radiol 2000, 35(3):154-167.
64. Krynetski E.Y., Tai H.L., Yates C.R., Fessing M.Y., Loennechen T., Schuetz J.D., Relling M.V., Evans W.E. Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms. Pharmacogenetics 1996, 6(4):279-290.
65. Kuhbacher T., Ott S.J., Helwig U., Mimura T., Rizzello F., Kleessen B., Gionchetti P., Blaut M., Campieri M., Folsch U.R., et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 2006, 55(6):833-841.
66. Kuster W., Pascoe L., Purrmann J., Funk S., Majewski F. The genetics of Crohn disease: Complex segregation analysis of a family study with 265 patients with Crohn disease and 5,387 relatives. Am J Med Genet 1989, 32(1):105-108.
67. Laharie D., Debeugny S., Peeters M., Van Gossum A., Gower-Rousseau C., Belaiche J., Fiasse R., Dupas J.L., Lerebours E., Piotte S., et al. Inflammatory bowel disease in spouses and their offspring. Gastroenterology 2001, 120(4):816-819.
68. Lakatos P.L., Fischer S., Claes K., Kovacs A., Molnar T., Altorjay I., Demeter P., Tulassay Z., Palatka K., Papp M. Hungarian IBD Study Group DLG5 R30Q is not associated with IBD in Hungarian IBD patients but predicts clinical response to steroids in Crohn's disease. Inflamm Bowel Dis 2006, 12(5):362-368.
69. Langholz E., Munkholm P., Davidsen M., Binder V. Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology 1994, 107(1):3-11.
70. Langholz E., Munkholm P., Krasilnikoff P.A., Binder V. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort. Scand J Gastroenterol 1997, 32(2):139-147.
71. Latiano A., Palmieri O., Valvano R.M., D'Inca R., Vecchi M., Ferraris A., Sturniolo G.C., Spina L., Lombardi G., Dallapiccola B., et al. Contribution of IBD5 locus to clinical features of IBD patients. Am J Gastroenterol 2006, 101(2):318-325.
72. Latour P., Louis E., Belaiche J. Incidence of inflammatory bowel disease in the area of Liege: A 3 years prospective study (1993-1996). Acta Gastroenterol Belg 1998, 61(4):410-413.
73. Lesage S., Zouali H., Cezard J.P., Colombel J.F., Belaiche J., Almer S., Tysk C., O'Morain C., Gassull M., Binder V., et al. EPWG-IBD Group; EPIMAD Group; GETAID Group CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet 2002, 70(4):845-857.
74. Loftus E.V. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology 2004, 126(6):1504-1517.
75. Louis E., Collard A., Oger A.F., Degroote E., Aboul Nasr E.L., Yafi F.A., Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: Changing pattern over the course of the disease. Gut 2001, 49(6):777-782.
76. Louis E., El Ghoul Z., Vermeire S., Dall'Ozzo S., Rutgeerts P., Paintaud G., Belaiche J., De Vos M., Van Gossum A., Colombel J.F., et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther 2004, 19(5):511-519.
77. Low J.H., Williams F.A., Yang X., Cullen S., Colley J., Ling K.L., Armuzzi A., Ahmad T., Neville M.J., Dechairo B.M., et al. Inflammatory bowel disease is linked to 19p13 and associated with ICAM-1. Inflamm Bowel Dis 2004, 10(3):173-181.
78. Margalit M., Israeli E., Shibolet O., Zigmond E., Klein A., Hemed N., Donegan J.J., Rabbani E., Goldin E., Ilan Y. A double-blind clinical trial for treatment of Crohn's disease by oral administration of Alequel, a mixture of autologous colon-extracted proteins: A patient-tailored approach. Am J Gastroenterol 2006, 101(3):561-568.
79. Martin N., Boomsma D., Machin G. A twin-pronged attack on complex traits. Nat Genet 1997, 17(4):387-392.
80. Mascheretti S., Hampe J., Croucher P.J., Nikolaus S., Andus T., Schubert S., Olson A., Bao W., Folsch U.R., Schreiber S. Response to infliximab treatment in Crohn's disease is not associated with mutations in the CARD15 (NOD2) gene: An analysis in 534 patients from two multicenter, prospective GCP-level trials. Pharmacogenetics 2002, 12(7):509-515.
81. Mascheretti S., Schreiber S. Genetic testing in Crohn disease: Utility in individualizing patient management. Am J Pharmacogenomics 2005, 5(4):213-222.
82. Medici V., Mascheretti S., Croucher P.J., Stoll M., Hampe J., Grebe J., Sturniolo G.C., Solberg C., Jahnsen J., Moum B., et al. Extreme heterogeneity in CARD15 and DLG5 Crohndisease-associated polymorphisms between German and Norwegian populations. Eur J Hum Genet 2006, 14(4):459-468.
83. Meucci G., Vecchi M., Torgano G., Arrigoni M., Prada A., Rocca F., Curzio M., Pera A., de Franchis R. Familial aggregation of inflammatory bowel disease in northern Italy: A multicenter study. The Gruppo di Studio per le Malattie Infiam-matorie Intestinali (IBD Study Group). Gastroenterology 1992, 103(2):514-519.
84. Mimura T., Rizzello F., Helwig U., Poggioli G., Schreiber S., Talbot I.C., Nicholls R.J., Gionchetti P., Campieri M., Kamm M.A. Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractorypouchitis. Gut 2004, 53(1):108-114.
85. Monsuur A.J., de Bakker P.I., Alizadeh B.Z., Zhernakova A., Bevova M.R., Strengman E., Franke L., van't Slot R., van Belzen M.J., Lavrijsen I.C., et al. Myosin IXB variant increases the risk of celiac disease and points toward a primary intestinal barrier defect. Nat Genet 2005, 37(12):1341-1344.
86. Moum B., Vatn M.H., Ekbom A., Aadland E., Fausa O., Lygren I., Sauar J., Schulz T., Stray N. Incidence of ulcerative colitis and indeterminate colitis in four counties of southeasternNorway, 1990-93. A prospective population-based study. The Inflammatory Bowel South-Eastern Norway (IBSEN) Study Group of Gastroenterologists. Scand J Gastroenterol 1996, 31(4):362-366.
87. Mow W.S., Vasiliauskas E.A., Lin Y.C., Fleshner P.R., Papadakis K.A., Taylor K.D., Landers C.J., Abreu-Martin M.T., Rotter J.I., Yang H., et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn's disease. Gastroenterology 2004, 126(2):414-424.
88. Munkholm P., Langholz E., Davidsen M., Binder V. Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut 1994, 35(3):360-362.
89. Munkholm P. Crohn's disease-occurrence, course and prognosis. An epidemiologic cohort-study. Dan Med Bull 1997, 44(3):287-302.
90. Neurath M.F., Fuss I., Kelsall B.L., Presky D.H., Waegell W., Strober W. Experimental granulomatous colitis in mice is abrogated by induction of TGF-beta-mediated oral tolerance. J Exp Med 1996, 183(6):2605-2616.
91. Neurath M.F., Kiesslich R., Teichgraber U., Fischer C., Hofmann U., Eichelbaum M., Galle P.R., Schwab M. 6-thioguanosine diphosphate and triphosphate levels in red blood cells and response to azathioprine therapy in Crohn's disease. Clin Gastroenterol Hepatol 2005, 3(10):1007-1014.
92. Newman B., Siminovitch K.A. Recent advances in the genetics of inflammatory bowel disease. Curr Opin Gastroenterol 2005, 21(4):401-407.
93. Newman W.G., Gu X., Wintle R.F., Liu X., van Oene M., Amos C.I., Siminovitch K.A. DLG5 variants contribute to Crohn disease risk in a Canadian population. Hum Mutat 2006, 27(4):353-358.
94. Noble C.L., Nimmo E.R., Drummond H., Smith L., Arnott I.D., Satsangi J. DLG5 variants do not influence susceptibility to inflammatory bowel disease in the Scottish population. Gut 2000, 54(10):1416-1420.
95. Noble C.L., Nimmo E.R., Drummond H., Ho G.T., Tenesa A., Smith L., Anderson N., Arnott I.D., Satsangi J. The contribution of OCTN1/2 variants within the IBD5 locus to disease susceptibility and severity in Crohn's disease. Gastroenterology 2005, 129(6):1854-1864.
96. Orchard T.R., Thiyagaraja S., Welsh K.I., Wordsworth B.P., Hill Gaston J.S., Jewell D.P. Clinical phenotype is related to HLA genotype in the peripheral arthropathies of inflammatory bowel disease. Gastroenterology 2000, 118(2):274-278.
97. Orchard T.R., Chua C.N., Ahmad T., Cheng H., Welsh K.I., Jewell D.P. Uveitis and erythema nodosum in inflammatory bowel disease: Clinical features and the role of HLA genes. Gastroenterology 2002, 123(3):714-718.
98. Orholm M., Munkholm P., Langholz E., Nielsen O.H., Sorensen I.A., Binder V. Familial occurrence of inflammatory bowel disease. N Engl J Med 1991, 324(2):84-88.
99. Orholm M., Binder V., Sorensen T.I., Rasmussen L.P., Kyvik K.O. Concordance of inflammatory bowel disease among Danish twins Results of a nationwide study. Scand J Gastroenterol 2000, 35(10):1075-1081.
100. Ogura Y., Bonen D.K., Inohara N., Nicolae D.L., Chen F.F., Ramos R., Britton H., Moran T., Karaliuskas R., Duerr R.H., et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 2001, 411(6837):603-606.
101. Ogura Y., Lala S., Xin W., Smith E., Dowds T.A., Chen F.F., Zimmermann E., Tretiakova M., Cho J.H., Hart J., et al. Expression of NOD2 in Paneth cells: A possible link to Crohn's ileitis. Gut 2003, 52(11):1591-1597.
102. Oudkerk Pool M., Ellerbroek P.M., Ridwan B.U., Goldschmeding R., von Blomberg B.M., Pena A.S., Dolman K.M., Bril H., Dekker W., Nauta J.J., et al. Serum antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease are mainly associated with ulcerative colitis. A correlation study between perinuclear antineutrophil cytoplasmic autoantibodies and clinical parameters, medical, and surgical treatment. Gut 1993, 34(1):46-50.
103. Peeters M., Nevens H., Baert F., Hiele M., de Meyer A.M., Vlietinck R., Rutgeerts P. Familial aggregation in Crohn's disease: Increased age-adjusted risk and concordance in clinical characteristics. Gastroenterology 1996, 111(3):597-603.
104. Peltekova V.D., Wintle R.F., Rubin L.A., Amos C.I., Huang Q., Gu X., Newman B., Van Oene M., Cescon D., Greenberg G., et al. Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat Genet 2004, 36(5):471-475.
105. Penner R., Fedorak R.N., Madsen K.L. Probiotics and nutraceuticals: Non-medicinal treatments of gastrointestinal diseases. Curr Opin Pharmacol 2005, 5(6):596-603.
106. Poppe D., Tiede I., Fritz G., Becker C., Bartsch B., Wirtz S., Strand D., Tanaka S., Galle P.R., Bustelo X.R. Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006, 176(1):640-651.
107. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., Podolsky D.K., Sands B.E., Braakman T., DeWoody K.L., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999 May 6, 340(18):1398-1405.
108. Reinhard C., Rioux J.D. Role of the IBD5 susceptibility locus in the inflammatory bowel diseases. Inflamm Bowel Dis 2006, 12(3):227-238.
109. Rioux J.D., Daly M.J., Silverberg M.S., Lindblad K., Steinhart H., Cohen Z., Delmonte T., Kocher K., Miller K., Guschwan S., et al. Genetic variation in the 5q31 cytokine gene cluster confers susceptibility to Crohn disease. Nat Genet 2001, 29(2):223-228.
110. Roth M.P., Petersen G.M., McElree C., Feldman E., Rotter J.I. Geographic origins of Jewish patients with inflammatory bowel disease. Gastroenterology 1989, 97(4):900-904.
111. Roussomoustakaki M., Satsangi J., Welsh K., Louis E., Fanning G., Targan S., Landers C., Jewell D.P. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997, 112(6):1845-1853.
112. Russel M.G., Dorant E., Volovics A., Brummer R.J., Pop P., Muris J.W., Bos L.P., Limonard C.B., Stockbrugger R.W. High incidence of inflammatory bowel disease in The Netherlands: Results of a prospective study. The South Limburg IBD Study Group. Dis Colon Rectum 1998, 41(1):33-40.
113. Russell R.K., Drummond H.E., Nimmo E.E., Anderson N., Smith L., Wilson D.C., Gillett P.M., McGrogan P., Hassan K., Weaver L.T., et al. Genotype-phenotype analysis in childhood-onset Crohn's disease: NOD2/CARD15 variants consistently predict phenotypic characteristics of severe disease. Inflamm Bowel Dis 2005, 11(11):955-964.
114. Sandborn W.J., Colombel J.F., Enns R., Feagan B.G., Hanauer S.B., Lawrance I.C., Panaccione R., Sanders M., Schreiber S., Targan S., et al. International Efficacy of Natalizumab as Active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as Continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005 Nov 3, 353(18):1912-1925.
115. Sands B.E., Blank M.A., Patel K., van Deventer S.J. ACCENT II study long-term treatment of rectovaginal fistulas in Crohn's disease: Response to infliximab in the ACCENT II Study. Clin Gastroenterol Hepatol 2004, 2(10):912-920.
116. Sans M., Artieda M., Diego T., Cara C., Rodrigo L., Barreiro M., Arroyo M.T., Aceituno M., Alvarez-Lobos M., Yague J., et al. IBDChip: A new strategy to predict clinical course and development of complications in patients with inflammatory bowel disease (IBD). Gastroenterology 2006, 130(4Suppl 2):A52-A53.
117. Satsangi J., Rosenberg W.M.C., Jewell D.P. The prevalence of inflammatory bowel disease in relatives of patients with Crohn's disease. Eur J Gastroenterol Hepatol 1994, 6:413-416.
118. Satsangi J., Welsh K.I., Bunce M., Julier C., Farrant J.M., Bell J.I., Jewell D.P. Contribution of genes of the major histocompatibility complex to susceptibility and disease phenotype in inflammatory bowel disease. Lancet 1996 May 4, 347(9010):1212-1217.
119. Schreiber S., Rosenstiel P., Albrecht M., Hampe J., Krawczak M. Genetics of Crohn disease, an archetypal inflammatory barrier disease. Nat Rev Genet 2005, 6(5):376-388.
120. Schulte C.M., Dignass A.U., Goebell H., Roher H.D., Schulte K.M. Genetic factors determine extent of bone loss in inflammatory bowel disease. Gastroenterology 2000, 119(4):909-920.
121. Shanahan F., Duerr R.H., Rotter J.I., Yang H., Sutherland L.R., McElree C., Landers C.J., Targan S.R. Neutrophil autoantibodies in ulcerative colitis: Familial aggregation and genetic heterogeneity. Gastroenterology 1992, 103(2):456-461.
122. Silverberg M.S., Daly M.J., Moskovitz D.N., Rioux J.D., McLeod R.S., Cohen Z., Greenberg G.R., Hudson T.J., Siminovitch K.A., Steinhart A.H. Diagnostic misclassification reduces the ability to detect linkage in inflammatory bowel disease genetic studies. Gut 2001, 49(6):773-776.
123. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R., Caprilli R., Colombel J.F., Gasche C., Geboes K., et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005, 19(Suppl A):5-36.
124. Stoll M., Corneliussen B., Costello C.M., Waetzig G.H., Mellgard B., Koch W.A., Rosenstiel P., Albrecht M., Croucher P.J., Seegert D., et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet 2004, 36(5):476-480.
125. Suenaert P., Bulteel V., Lemmens L., Noman M., Geypens B., Van Assche G., Geboes K., Ceuppens J.L., Rutgeerts P. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002, 97(8):2000-2004.
126. Tato C.M., O'Shea J.J. Immunology: What does it mean to be just 17?. Nature 2006 May 11, 441(7090):166-168.
127. Tenesa A., Noble C., Satsangi J., Dunlop M. Association of DLG5 and inflammatory bowel disease across populations. Eur J Hum Genet 2006, 14(3):259-260.
128. Thjodleifsson B., Sigthorsson G., Cariglia N., Reynisdottir I., Gudbjartsson D.F., Kristjansson K., Meddings J.B., Gudnason V., Wandall J.H., Andersen L.P., et al. Subclinical intestinal inflammation: An inherited abnormality in Crohn's disease relatives?. Gastroenterology 2003, 124(7):1728-1737.
129. Timmer A., Goebell H. Incidence of ulcerative colitis, 1980-1995. A prospective study in an urban population in Germany. Z Gastroenterol 1999, 37(11):1079-1084.
130. Timmer A., Breuer-Katschinski B., Goebell H. Time trends in the incidence and disease location of Crohn's disease 1980-1995: A prospective analysis in an urban population in Germany. Inflamm Bowel Dis 1999, 5(2):79-84.
131. Torok H.P., Glas J., Tonenchi L., Lohse P., Muller-Myhsok B., Limbersky O., Neugebauer C., Schnitzler F., Seiderer J., Tillack C., et al. Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn's disease. Gut 2005, 54(10):1421-1427.
132. Tremelling M., Waller S., Bredin F., Greenfield S., Parkes M. Genetic variants in TNF-alpha but not DLG5 are associated with inflammatory bowel disease in a large United Kingdom cohort. Inflamm Bowel Dis 2006, 12(3):178-184.
133. Turner D., Walsh C.M., Steinhart A.H., Griffiths A.M. Response to corticosteroids in severe ulcerative colitis: A systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007, 5(1):103-110.
134. Tysk C., Lindberg E., Jarnerot G., Floderus-Myrhed B. Ulcerative colitis and Crohn's disease in an unselected population of monozygotic and dizygotic twins. A study of heritability and the influence of smoking. Gut 1988, 29(7):990-996.
135. Urano W., Taniguchi A., Yamanaka H., Tanaka E., Nakajima H., Matsuda Y., Akama H., Kitamura Y., Kamatani N. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002, 12(3):183-190.
136. Urcelay E., Mendoza J.L., Martinez A., Fernandez L., Taxonera C., Diaz-Rubio M., de la Concha E.G. IBD5 polymorphisms in inflammatory bowel disease: Association with response to infliximab. World J Gastroenterol 2005, 11(8):1187-1192.
137. Van Assche G., Rutgeerts P. Antiadhesion molecule therapy in inflammatory bowel disease. Inflamm Bowel Dis 2002, 8(4):291-300.
138. van Bodegraven A.A., Curley C.R., Hunt K.A., Monsuur A.J., Linskens R.K., Onnie C.M., Crusius J.B., Annese V., Latiano A., Silverberg M.S., et al. Genetic variation in myosin IXB is associated with ulcerative colitis. Gastroenterology 2006, 131(6):1768-1774.
139. Van Heel D.A., Fisher S.A., Kirby A., Daly M.J., Rioux J.D., Lewis C.M.
140. Venturi A., Gionchetti P., Rizzello F., Johansson R., Zucconi E., Brigidi P., Matteuzzi D., Campieri M. Impact on the composition of the faecal flora by a new probiotic preparation: Preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999, 13(8):1103-1108.
141. Vermeire S., Peeters M., Vlietinck R., Joossens S., Den Hond E., Bulteel V., Bossuyt X., Geypens B., Rutgeerts P. Anti-Saccharomyces cerevisiae antibodies (ASCA), phenotypes of IBD, and intestinal permeability: A study in IBD families. Inflamm Bowel Dis 2001, 7(1):8-15.
142. Vermeire S., Louis E., Rutgeerts P., De Vos M., Van Gossum A., Belaiche J., Pescatore P., Fiasse R., Pelckmans P., Vlietinck R., et al. Belgian Group of Infliximab Expanded Access Program and Fondation Jean Dausset CEPH, Paris, France. NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology 2002, 123(1):106-111.
143. Vermeire S. NOD2/CARD15: Relevance in clinical practice. Best Pract Res Clin Gastroenterol 2004, 18(3):569-575.
144. Vermeire S., Pierik M., Hlavaty T., Claessens G., van Schuerbeeck N., Joossens S., Ferrante M., Henckaerts L., Bueno de Mesquita M., Vlietinck R., et al. Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD. Gastroenterology 2005, 129(6):1845-1853.
145. Vermeire S., Rutgeerts P. Current status of genetics research in inflammatory bowel disease. Genes Immun 2005, 6(8):637-645.
146. Wehkamp J., Harder J., Weichenthal M., Schwab M., Schaffeler E., Schlee M., Herrlinger K.R., Stallmach A., Noack F., Fritz P., et al. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut 2004, 53(11):1658-1664.
147. Wild G.E., Rioux J.D. Genome scan analyses and positional cloning strategy in IBD: Successes and limitations. Best Pract Res Clin Gastroenterol 2004, 18(3):541-553.
148. Witte J., Shivananda S., Lennard-Jones J.E., Beltrami M., Politi P., Bonanomi A., Tsianos E.V., Mouzas I., Schulz T.B., Monteiro E., et al. Disease outcome in inflammatory bowel disease: Mortality, morbidity and therapeutic management of a 796-person inception cohort in the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Scand J Gastroenterol 2000, 35(12):1272-1277.
149. Yamazaki K., Takazoe M., Tanaka T., Ichimori T., Saito S., Iida A., Onouchi Y., Hata A., Nakamura Y. Association analysis of SLC22A4, SLC22A5 and DLG5 in Japanese patients with Crohn disease. J Hum Genet 2004, 49(12):664-668.
150. Yang H., McElree C., Roth M.P., Shanahan F., Targan S.R., Rotter J.I. Familial empirical risks for inflammatory bowel disease: Differences between Jews and non-Jews. Gut 1993, 34(4):517-524.
151. Yang P., Jarnerot G., Danielsson D., Tysk C., Lindberg E. P-ANCA in monozygotic twins with inflammatory bowel disease. Gut 1995, 36(6):887-890.
152. Yang X., Cullen S.N., Li J.H., Chapman R.W., Jewell D.P. Susceptibility to primary sclerosing cholangitis is associated with polymorphisms of intercellular adhesion molecule-1. J Hepatol 2004, 40(3):375-379.
153. Yates C.R., Krynetski E.Y., Loennechen T., Fessing M.Y., Tai H.L., Pui C.H., Relling M.V., Evans W.E. Molecular diagnosis of thiopurine S-methyltransferase deficiency: Genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997 Aug 15, 126(8):608-614.